Consequently, new therapeutic strategies are required. Pippa Newell and colleagues found that molecular alterations of the Ras pathway are common in HCC and that the multikinase inhibitor ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Dogs that have oral squamous cell carcinomas often need surgery that disfigures their jaws and lower their quality of ...

Abstract 4367 – ERAS-4001 is a pan-KRAS inhibitor with robust anti-tumor activity in KRAS altered solid tumors Date/Time: Tuesday, April 29, 2025, 9 AM – 12 PM CDT Session: Experimental and Molecular ...

Fintel reports that on March 26, 2025, Raymond James initiated coverage of Erasca (NasdaqGS:ERAS) with a Outperform ...

The results demonstrate that compared to avutometinib alone, the FAK inhibitor/avutometinib combination inhibits RAS/MAPK pathway signaling more deeply while also blocking key adaptive resistance ...

A new review was published in , Volume 16, on March 13, 2025, titled "Signaling pathway dysregulation in breast cancer." ...

Innovations in therapeutic strategies, coupled with a deeper understanding of breast cancer biology, will be essential for advancing personalized ...

Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Date and Time: Wednesday, April 30, 2025; 9:00 AM - 12:00 PM ...

Dogs that have oral squamous cell carcinomas often need surgeries that disfigure their jaws and lower their quality of life - and in 20% of dogs ...

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with ...